Tags

Type your tag names separated by a space and hit enter

Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
HIV Med 2007; 8(3):156-63HM

Abstract

BACKGROUND

The increase in CD4 count may reach a plateau after some duration of virological response to highly active antiretroviral therapy (HAART).

METHODS

A total of 1281 HIV-infected patients initiating HAART were enrolled in the AntiPROtease (APROCO) cohort. We investigated determinants of increase in CD4 count using longitudinal mixed models in patients who maintained a plasma HIV RNA <500 HIV-1 RNA copies/mL.

RESULTS

A total of 870 patients had a virological response at month 4. The median follow-up time was 57 months. Mean estimated increases in CD4 count in patients with persistent virological response were 29.9 cells/muL/month before month 4, 6.4 cells/microL/month between months 4 and 36, and 0.7 cells/microL/month (not significantly different from 0) after month 36. Three factors were associated with a significantly positive CD4 count slope after month 36: male gender (+0.9), no history of antiretroviral therapy at baseline (+1.7) and baseline CD4 count <100 cells/microL (+2.6). In patients who maintained a virological response after 5 years of HAART, a CD4 count >500 cells/microL was achieved in 83% of those with a baseline CD4 count >or=200 cells/microL and in 45% of those with a baseline CD4 count <200 cells/microL.

CONCLUSION

The increase in CD4 count reaches a plateau after 3 years of virological response. Even if patients initiating HAART with low CD4 counts still show a CD4 count increase after 3 years, it remains insufficient to overcome immune deficiency in all patients.

Authors+Show Affiliations

Service des Maladies Infectieuses et Tropicales, Hôpital Gui de Chauliac, Centre Hospitalier Universitaire, Montpellier, France. v-le_moing@chu-montpellier.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

17461859

Citation

Le Moing, V, et al. "Long-term Evolution of CD4 Count in Patients With a Plasma HIV RNA Persistently <500 copies/mL During Treatment With Antiretroviral Drugs." HIV Medicine, vol. 8, no. 3, 2007, pp. 156-63.
Le Moing V, Thiébaut R, Chêne G, et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med. 2007;8(3):156-63.
Le Moing, V., Thiébaut, R., Chêne, G., Sobel, A., Massip, P., Collin, F., ... Raffi, F. (2007). Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Medicine, 8(3), pp. 156-63.
Le Moing V, et al. Long-term Evolution of CD4 Count in Patients With a Plasma HIV RNA Persistently <500 copies/mL During Treatment With Antiretroviral Drugs. HIV Med. 2007;8(3):156-63. PubMed PMID: 17461859.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. AU - Le Moing,V, AU - Thiébaut,R, AU - Chêne,G, AU - Sobel,A, AU - Massip,P, AU - Collin,F, AU - Meyohas,Mc, AU - Al Kaïed,F, AU - Leport,C, AU - Raffi,F, AU - ,, PY - 2007/4/28/pubmed PY - 2007/12/21/medline PY - 2007/4/28/entrez SP - 156 EP - 63 JF - HIV medicine JO - HIV Med. VL - 8 IS - 3 N2 - BACKGROUND: The increase in CD4 count may reach a plateau after some duration of virological response to highly active antiretroviral therapy (HAART). METHODS: A total of 1281 HIV-infected patients initiating HAART were enrolled in the AntiPROtease (APROCO) cohort. We investigated determinants of increase in CD4 count using longitudinal mixed models in patients who maintained a plasma HIV RNA <500 HIV-1 RNA copies/mL. RESULTS: A total of 870 patients had a virological response at month 4. The median follow-up time was 57 months. Mean estimated increases in CD4 count in patients with persistent virological response were 29.9 cells/muL/month before month 4, 6.4 cells/microL/month between months 4 and 36, and 0.7 cells/microL/month (not significantly different from 0) after month 36. Three factors were associated with a significantly positive CD4 count slope after month 36: male gender (+0.9), no history of antiretroviral therapy at baseline (+1.7) and baseline CD4 count <100 cells/microL (+2.6). In patients who maintained a virological response after 5 years of HAART, a CD4 count >500 cells/microL was achieved in 83% of those with a baseline CD4 count >or=200 cells/microL and in 45% of those with a baseline CD4 count <200 cells/microL. CONCLUSION: The increase in CD4 count reaches a plateau after 3 years of virological response. Even if patients initiating HAART with low CD4 counts still show a CD4 count increase after 3 years, it remains insufficient to overcome immune deficiency in all patients. SN - 1464-2662 UR - https://www.unboundmedicine.com/medline/citation/17461859/Long_term_evolution_of_CD4_count_in_patients_with_a_plasma_HIV_RNA_persistently_<500_copies/mL_during_treatment_with_antiretroviral_drugs_ L2 - https://doi.org/10.1111/j.1468-1293.2007.00446.x DB - PRIME DP - Unbound Medicine ER -